---
title: 'Adjunctive Glucocorticoid Therapy for Pneumocystis jirovecii Pneumonia in
  Solid Organ Transplant Recipients: A Multicenter Cohort, 2015-2020'
date: '2023-11-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37977229/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231118170631&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'Solid organ transplant recipients (SOTRs) frequently receive adjunctive
  glucocorticoid therapy (AGT) for Pneumocystis jirovecii pneumonia (PJP). This multicenter
  cohort of SOTRs with PJP admitted to 20 transplant centers in Canada, the United
  States, Europe, and Australia, examined whether AGT was associated with a lower
  rate of all-cause intensive care unit (ICU) admission, 90-day in-hospital death,
  or a composite outcome (ICU admission or death). Of 172 SOTRs with PJP [median (IQR)
  age: ...'
disable_comments: true
---
Solid organ transplant recipients (SOTRs) frequently receive adjunctive glucocorticoid therapy (AGT) for Pneumocystis jirovecii pneumonia (PJP). This multicenter cohort of SOTRs with PJP admitted to 20 transplant centers in Canada, the United States, Europe, and Australia, examined whether AGT was associated with a lower rate of all-cause intensive care unit (ICU) admission, 90-day in-hospital death, or a composite outcome (ICU admission or death). Of 172 SOTRs with PJP [median (IQR) age: ...